Does patient sex play a role in treatment-free remission in chronic myeloid leukemia?

Does patient sex play a role in treatment-free remission in chronic myeloid leukemia? Int J Hematol. 2020 Mar 21;: Authors: Ureshino H, Kamachi K, Kimura S PMID: 32200529 [PubMed - as supplied by publisher]
Source: International Journal of Hematology - Category: Hematology Authors: Tags: Int J Hematol Source Type: research

Related Links:

Today I'll point out an example of drug reuse and autophagy upregulation. The processes of autophagy are responsible for recycling molecular waste and broken cellular structures. Autophagy is upregulated in response to stress placed upon cells, whether by heat, cold, lack of nutrients, a toxic local environment, and so forth. This is beneficial to tissue function, health, and longevity, and thus there is considerable interest in the research community in producing therapies that boost the operation of autophagy. This hasn't made a great deal of progress towards the clinic, but nonetheless in any of the sizable databases of...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is now managed as a chronic disease requiring long-term treatment and close molecular monitoring. It has been shown that in a substantial number of patients who have achieved a stable deep molecular response (DMR), TKI treatment can be safely discontinued without loss of response. Therefore, treatment-free remission (TFR), through the achievement of a DMR, is increasingly regarded as a feasible treatment goal in many CML patients. However, only nilotinib...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractIntroductionThis comprehensive observational study aimed to gain insight into adherence to nilotinib and the effect of (non)adherence on exposure (Cmin) and treatment outcomes.MethodsChronic myeloid leukemia (CML) patients using nilotinib were followed for 12 months. Adherence was measured by Medication Event Monitoring System (MEMS), pill count, and Medication Adherence Report Scale (MARS-5). NilotinibCmin and patient-reported outcomes (i.e., quality of life, side effects, beliefs, satisfaction) were measured at baseline, 3, 6, and 12 months.ResultsSixty-eight patients (57.5 ± 15.0 years, 49% female) partic...
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: In our case, the CML-related retinopathy represented the onset sign of the underlying systemic pathology, leading to proper management and treatment, with hematological normalization and resolution of the retinopathy. PMID: 32476461 [PubMed - as supplied by publisher]
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Eur J Ophthalmol Source Type: research
This study demonstrated the critical role of the ABL gene in maintaining CML cell survival and tumorigenicity in vitro and in vivo. ABL gene editing-based therapy might provide a potential strategy for imatinib-insensitive or resistant CML patients.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Revised Funding Information.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Conclusion: Monocytopenia, especially anemia, was the most common type of cytopenia. The cytopenia was predominantly grade 2, developed in majority of the patients within 6 months after imatinib initiation, and had resolved by 24-36 months after imatinib initiation. PMID: 32454829 [PubMed]
Source: Advances in Hematology - Category: Hematology Tags: Adv Hematol Source Type: research
The advent of tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the treatment of chronic myeloid leukemia (CML) patients. However, cardiotoxicity associated with these targeted therapies puts the cancer survivors at higher risk. Ponatinib is a third-generation TKI for the treatment of CML patients having gatekeeper mutation T315I, which is resistant to the first and second generation of TKIs, namely, imatinib, nilotinib, dasatinib, and bosutinib. Multiple unbiased screening from our lab and others have identified ponatinib as most cardiotoxic FDA approved TKI among the entire FDA approved TKI family (total 50+).
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Contributors : Daisuke Kodama ; Masakazu Tanaka ; Toshio Matsuzaki ; Kimiko Izumo ; Nobuaki Nakano ; Eiji Matsuura ; Mineki Saito ; Masahiro Nagai ; Masahisa Horinouchi ; Atae Utsunomiya ; Hiroshi Takashima ; Ryuji Kubota ; Shuji IzumoSeries Type : Expression profiling by arrayOrganism : Homo sapiensHuman T-cell leukemia virus type 1 (HTLV-1) causes incurable adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Patients with HAM/TSP have increased levels of HTLV-1-infected cells compared with asymptomatic HTLV-1 carriers. However, the roles played by cellular genes in HTLV-1-infect...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
AbstractInherited polymorphic sequence variations in drug transport genes likeABCB1 impact a portion of patients with hematologic malignancies that show intrinsic or acquire resistance to treatment. Keeping in view inter-individual sensitivities for such drugs, we through this case –control study tested whetherABCB1 C3435T and G2677T polymorphisms have any influence on the risk and treatment response in patients with chronic myeloid leukemia (CML) and B-acute lymphoblastic leukemia (B-ALL). Genotyping forABCB1 polymorphisms was performed by polymerase chain reaction-restriction fragment length polymorphism in 100 CML...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia